Chengdu Olymvax Biopharmaceuticals (SH:688319) Zheng Quan Zhi Xing·2025-08-18 16:17Core Viewpoint - Chengdu Olin Biological Technology Co., Ltd. plans to issue A-shares to specific investors, which may dilute immediate returns, and has proposed measures to compensate for this dilution [1][5]. Financial Impact of the Issuance - The issuance is expected to impact key financial metrics, with three scenarios analyzed for the net profit attributable to shareholders in 2025 compared to 2024: a 10% increase, no change, and a 10% decrease [2][3][4]. - In the first scenario, the net profit would rise to CNY 22.83 million, with basic and diluted earnings per share (EPS) at CNY 0.0559 [3]. - In the second scenario, the net profit remains at CNY 20.76 million, with basic and diluted EPS at CNY 0.0508 [4]. - In the third scenario, the net profit would drop to CNY 18.68 million, with basic and diluted EPS at CNY 0.0458 [4]. Necessity and Reasonableness of the Issuance - The funds raised will be used for a vaccine R&D production base technology renovation project, which aligns with the company's core business and development strategy [5][6]. - The project aims to enhance production capabilities and ensure stable revenue generation, supporting long-term R&D and market promotion [5][6]. Company’s Preparedness in Talent, Technology, and Market - The company has a stable management team with extensive experience in the biopharmaceutical industry, ensuring ongoing support for sustainable development [6][7]. - The R&D team has over ten years of experience in vaccine development, focusing on both traditional and innovative vaccine projects [7][8]. - The company has established multiple vaccine R&D platforms and holds several patents, enhancing its competitive edge in the market [8]. Measures to Mitigate Dilution of Immediate Returns - The company commits to maintaining stable and rapid growth in its core business and accelerating the investment progress of the fundraising projects to enhance profitability [9][12]. - It will manage the raised funds strictly according to legal regulations to ensure compliance and effective use [11][12]. - The company plans to improve its profit distribution policy to ensure reasonable returns for investors, particularly small shareholders [12][13]. Commitments from Major Stakeholders - The controlling shareholder and actual controller have made commitments to uphold the company's independence and ensure the fulfillment of compensation measures for diluted returns [14][15]. - The board of directors and senior management have also pledged to avoid actions that could harm the company's interests and to adhere to the commitments made regarding return compensation [15][17].